Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

Full story: BioSpace
Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more) Full Story

Singapore, Singapore

#1 Jul 11, 2012
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.

Singapore, Singapore

#2 Jul 17, 2012
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated:

Subscribe Now Add to my Tracker

Add your comments below

Characters left: 4000

Please note by submitting this form you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

Biotech Discussions

Title Updated Last By Comments
Phosphorous detection from compost/soil Jan 28 Pushkar Bhojane 1
LabCorp finalizes merger deal with LipoScience Jan 26 Bill Taylor 1
Solano Community College awaits word on biotech... Jan 21 Birds Landing Bob 1
Injectable drug may help fight obesity Jan 20 mathewsteven10 4
Company seeks approval for skin cancer drug Jan 8 Cathy Smith 1
Viagra may work for women, too (Jul '08) Jan 7 Galos 26
Safety trial of Ebola vaccine under way in England Jan 7 Thx 1
More from around the web